Eris Lifesciences Limited — Important, 20-02-2026: Updates

Eris Lifesciences strategically expanded into Diabesity and global markets with over INR 4,300 Cr in acquisitions. The company anticipates accelerated EPS growth going forward and aims for a debt-to-EBITDA ratio under 1.5x by year-end. Robust international business, particularly EU-CDMO with significant future revenue, coupled with margin expansion to 36%, positions for strong performance.